Designing the future shape of breast cancer diagnosis, prognosis and treatment

Breast Cancer Research and Treatment

Volumn 87, Issue SUPPL., 2004, Pages

  Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Breast cancer; Clinical trial; Genomic; Preoperative; TA01 program

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; DISEASE MARKER; GENOMICS; HUMAN; METHODOLOGY; MOLECULAR DYNAMICS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

EID: 12144252782     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-1580-9     Document Type: Review

References (8)

1. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC: Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63: 2434-2439, 2003
2. Nicholson RI, Gee JMW, Knowlden J, McClelland R, Madden T, Barrow D, Hutcheson I: The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80(Suppl 1): S29-S34, 2003
3. van't Veer LJ, Dai H. van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marion MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002
4. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009, 2002
5. Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, Arciero C, Brzeski H, Hooke J, Shriver C: High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3: 1863-1873, 2003
6. Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N, Grigorian M, Lukanidin E, Thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jaattela M, Roepstorff P, Bolund L, Orntoft T, Brunner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE: Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research. Mol Cell Proteomics 2: 369-377, 2003
7. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002
8. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802-1810, 2003